{
    "nct_id": "NCT03435081",
    "official_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis",
    "inclusion_criteria": "* Have a diagnosis of atopic dermatitis (AD) at least 12 months before screening.\n* Have moderate to severe AD, including all of the following:\n\n  * EASI score ≥16\n  * IGA score of ≥3\n  * ≥10% of BSA involvement\n* Have had inadequate response or intolerance to existing topical (applied to the skin) medications within 6 months preceding screening.\n* Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a washout period).\n* Agree to use emollients daily.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory, or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.\n* A history of eczema herpeticum within 12 months, and/or a history of 2 or more episode of eczema herpeticum in the past.\n* Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.\n* Have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).\n* Have been treated with the following therapies:\n\n  * monoclonal antibody for less than 5 half-lives before randomization\n  * received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4 weeks before randomization\n  * received any parenteral corticosteroid administered by intramuscular or intravenous injection within 6 weeks of planned randomization or are anticipated to require parenteral injection of corticosteroids during the study\n  * have had an intra-articular corticosteroid injection within 6 weeks of planned randomization\n  * probenecid at the time of randomization that cannot be discontinued for the duration of the study\n* Have high blood pressure characterized by a repeated systolic blood pressure >160 millimeters of mercury (mm Hg) or diastolic blood pressure >100 mm Hg.\n* Have had major surgery within the past eight weeks or are planning major surgery during the study.\n* Have experienced any of the following within 12 weeks of screening: myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.\n* Have a history of venous thromboembolic event (VTE), or are considered at high risk for VTE.\n* Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.\n* Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.\n* Have specific laboratory abnormalities.\n* Have received certain treatments that are contraindicated.\n* Pregnant or breastfeeding.",
    "miscellaneous_criteria": ""
}